This is particularly relevant for HF patients with preserved ejection fraction, given evolving evidence showing that sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and mineralocorticoid receptor antagonists prevent death and HF hospitalizations, while also improving patients' health status.7, 8, 9. The gene discussed is GLP1R; the disease is hydrops fetalis.